This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.A Phase I trial of a human IgM monoclonal antibody (MAb216) that kills B lineage cells including acute B lymphoblastic leukemia, with or without complement. Trial will study safety, pharmacokinetics and anti-tumor acitivity of the antibody given as a single agent and with vincristine in adult patients with relapsed or refractory B lineage ALL.
Showing the most recent 10 out of 589 publications